FUZHOU, China, Feb. 6, 2026 /PRNewswire/ — E-Home Household Services Holdings Limited (NASDAQ:EJH) (the “Company” or “eHome”), an integrated home services provider in China, announced today that the company will fully leverage new tax incentives to enhance financial management, strengthen training for domestic service personnel, improve service quality, and introduce AI technology. The company will progressively roll out a human-machine integrated service model and make effective use of tax benefits to increase staff deployment rates, propelling its performance to new heights by 2026.

Key support directions for China’s 2026 tax policies targeting the domestic service industry: 1. Domestic service enterprises may benefit from a reduction or exemption of VAT on income derived from providing domestic services, as stipulated. 2. Social insurance contributions paid by enterprises for their employees are deductible when calculating taxable income, thereby reducing corporate tax burdens. 2. Eligible home service enterprises may benefit from preferential corporate income tax rates. Training expenses incurred by enterprises for home service personnel can be deducted at an increased rate when calculating taxable income, which encourages enterprises to enhance the skills of home service workers. 3. Taxpayers who support elderly dependants or raise children may qualify for special additional deductions under personal income tax regulations, which indirectly stimulates demand for home services.

Mr. Wenshan Xie, Chairman and CEO of E-Home, commented: “The specific benefits of the 2026 tax reform for the domestic service industry are as follows: 1. Reducing corporate operating costs directly lowers the tax burden on domestic service enterprises, freeing up more capital for improving service conditions, enhancing compensation for domestic workers, and elevating service quality. 2. Stimulating market demand through the special additional deductions for individual income tax alleviates the financial burden of family elder care and childcare, thereby boosting demand for domestic services and expanding the industry’s market potential. 3. Standardizing industry development: Policy implementation compels home service enterprises to strengthen financial management and compliant operations, driving the industry toward standardization and professionalization. Tax reform will promote sustainable industry growth, enhance societal recognition of the sector, and spur innovative development.”

About E-Home Household Service Holdings Limited

Established in 2014, E-Home Household Service Holdings Limited is a Nasdaq-listed household service company based in Fuzhou, China.

The company is mainly involved in: 1. Home appliances, smart home installation, maintenance; 2. Housekeeping, nannies, maternity matron and cleaning services; 3. Internet aging + home care; 4. Units of public places cleaning. After years of development, E-Home has formed two main business channels, ToB and ToC, with two important subsidiaries.

Two main channels: 1. The ToC business to nanny, maternity matron, home care, cleaning, repair, maintenance of family integrated services. 2. The ToB business to public cleaning. Two subsidiaries: 1. Zhongrun Pharmaceutical, integrating pharmaceutical warehousing, distribution, wholesaling, retailing, and online sales; 2. Chuangying: presidential training, internal training, corporate consulting and counseling, and policy counseling. E-Home has been a comprehensive service enterprise for family life! We have always adhered to the “solving every issue of customers with heart” business philosophy, adhere to do the industry benchmark. For more information, visit the Company’s website at http://www.ej111.com/ir.html. 

Forward-Looking Statement

All statements other than statements of historical fact in this announcement are forward-looking statements in nature within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions are intended to identify such forward-looking statements. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to consider risk factors, including those described in the Company’s filings with the SEC, that may affect the Company’s future results. All forward-looking statements attributable to the Company and its subsidiaries or persons acting on their behalf are expressly qualified in their entirety by these risk factors.

CAMBRIDGE, Mass., Feb. 6, 2026 /PRNewswire/ — Insilico Medicine (“Insilico”)  (3696.HK),  a clinical-stage biotechnology company powered by generative artificial intelligence (AI), today announced the appointment of Halle Zhang, PhD (Med), as Vice President, Clinical Development – Oncology. Dr. Zhang will report to Feng Ren, Co-Chief Executive Officer and Chief Scientific Officer of Insilico Medicine, and will be based in the company’s Cambridge, Massachusetts office.

In this role, Dr. Zhang will lead the global clinical development strategy and execution for Insilico’s oncology portfolio, guiding both early- and late-stage programs across multiple tumor types. She will also contribute to broader portfolio planning and the company’s growth strategy, partnering closely with discovery, translational, biomarker, regulatory, and clinical operations teams to accelerate development timelines and deliver differentiated, patient-centered therapies.

Dr. Zhang is a strategic leader in oncology clinical development with more than 20 years of experience spanning academia, biotechnology, and the pharmaceutical industry. Most recently, she served as Global Clinical Development Program Leader for late-stage oncology and Global Program Leader for early oncology at Bristol Myers Squibb, where she was accountable for global development strategy and execution across multiple solid tumor indications, including lung, breast, melanoma, gastric, colorectal, bladder, and head and neck cancers. Her experience spans diverse therapeutic modalities, including immuno-oncology–based approaches, targeted small-molecule therapies, and antibody–drug conjugates (ADCs), leading programs from first-in-human studies through registrational trials.

She worked closely with global regulatory authorities to shape development strategies, optimize study design, and support regulatory submissions, while integrating translational science and biomarker strategies into clinical plans. Over the course of her career, she has built and scaled high-performing clinical development organizations and is recognized for fostering a culture of scientific rigor, accountability, and collaboration.

Earlier, Dr. Zhang held senior clinical development leadership roles at Infinity Pharmaceuticals and BioMed Valley Discoveries and began her career in academic research and clinical operations at Harvard Medical School, where she led NIH-sponsored clinical trials. She holds a PhD in Medicine and an MSc in Immunology and Microbiology from University of Birmingham, and a BSc in Nursing from University of Portsmouth.

“Halle brings exceptional scientific depth, strategic judgment, and operational excellence to Insilico’s oncology programs,” said Alex Zhavoronkov, PhD, Founder and CEO of Insilico Medicine. “Her proven leadership across global oncology development will be instrumental as we continue to expand our AI-driven pipeline and translate innovative science into meaningful clinical outcomes for patients.”

“I am excited to join Insilico Medicine at such an important stage of growth,” said Dr. Zhang. “Insilico’s unique AI-driven platform, combined with a bold, science-first culture, creates a powerful opportunity to rethink how oncology medicines are discovered and developed. I look forward to partnering with this talented team to advance therapies that address significant unmet needs for patients.”

Over the past year, Insilico Medicine’s oncology pipelines have been moving forward with high efficiency. Several innovative pipelines designed and optimized with the help of Chemistry42 have progressed to Phase I clinical trials. In January 2025, ISM6331, a pan-TEAD inhibitor with an innovative structure, was announced to have completed first patient dosing in a global, multicenter Phase I clinical trial for the treatment of mesothelioma and other solid tumors. In June 2025, ISM3412, a potential “best-in-class” inhibitor targeting MAT2A, was announced to have completed first patient dosing in patients with locally advanced and metastatic solid tumors, aiming to evaluate safety, tolerability, PK/PD characteristics, and preliminary efficacy.

In addition to advancing its internal pipeline, Insilico Medicine and its global partners have achieved multiple milestones across collaborative oncology programs. The company entered a multi-program discovery and development collaboration with Servier valued at up to USD $888 million to leverage Insilico’s AI platform to generate first-in-class small-molecule cancer therapies. Under its collaboration totaling up to USD $550 million with Menarini Group, Insilico received a USD $3 million development and regulatory milestone payment in July 2025, followed by a USD $5 million milestone upon dosing the first patient in the Phase I clinical trial of MEN2501 (ISM9682), a highly differentiated KIF18A small-molecule inhibitor.

Harnessing state-of-the-art AI and automation technologies, Insilico has significantly improved the efficiency of preclinical drug development. While traditional early-stage drug discovery typically requires 3 to 6 years, from 2021 to 2024 Insilico nominated 20 preclinical candidates, achieving an average turnaround – from project initiation to preclinical candidate (PCC) nomination – of just 12 to 18 months per program, with only 60 to 200 molecules synthesized and tested in each program.

About Insilico Medicine

Insilico Medicine, a leading and global AI-driven biotech company, utilizes its proprietary Pharma.AI platform and cutting-stage automated laboratory to accelerate drug discovery and advance innovations in life sciences research. By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma.AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine. For more information, please visit www.insilico.com.

SHENZHEN, China, Feb. 6, 2026 /PRNewswire/ — MicroCloud Hologram Inc. (NASDAQ: HOLO), (“HOLO” or the “Company”), a technology service provider, developed a transmission scheme for GHZ states and W states based on Brownian state quantum channels. This scheme establishes an efficient transmission mechanism for multi-particle entangled states by constructing special quantum channels and measurement systems. At the technical implementation level, HOLO uses quantum Fourier transform for quantum state projection measurement and precisely designs the sequence of quantum gate operations required for reconstructing quantum states at the receiving end. This technical scheme not only perfects the theoretical system of quantum teleportation but also provides new technical paths for information transmission in large-scale quantum systems, promoting the development of quantum communication technology toward practicalization.

In terms of technical architecture design, the implementation of the Brownian state quantum channel demonstrates significant innovation. The Brownian state is a special four-particle entangled state, whose characteristics are very suitable for constructing quantum transmission channels. HOLO utilizes this entanglement characteristic to establish stable quantum links. When transmitting the three-particle GHZ state, the sender performs joint measurement on the quantum state to be transmitted and specific particles in the Brownian state, which establishes quantum correlation between the transmission state and the channel state. The key to technical implementation lies in using specially designed measurement devices to make the measurement results form a definite correspondence with the channel state. This design enables the receiver to select the corresponding quantum gate operations to reconstruct the original quantum state based on the measurement results transmitted through the classical channel.

The quantum Fourier transform plays a key role in this protocol, and its technical implementation has unique advantages. The research team adopts the quantum Fourier transform to construct the basic measurement framework required for projection measurement; this method has better system adaptability compared to traditional measurement methods. Through this mathematical transformation method, researchers can map quantum states to a set of standard measurement bases, thereby achieving accurate measurement of quantum states. In actual operation, this transformation is realized through an ordered combination of a series of quantum logic gates, and its system complexity maintains a reasonable relationship with the number of qubits, ensuring the scalability of the scheme.

In the design and implementation stage of quantum gate operations, HOLO has established complete technical specifications. Based on quantum mechanics principles, the research team accurately calculates all quantum gate operations that the receiving end needs to execute to reconstruct the quantum state. For the transmission of GHZ states, these operations include the combined application of specific types of phase gates and controlled-NOT gates; whereas for the transmission of W states, it is necessary to implement more complex multi-particle control operations. Technical documents show that all quantum gate operations can be represented using a standard quantum gate set; this representation method simplifies the operation process and facilitates implementation on different quantum hardware platforms. The research team has also verified the feasibility of these quantum gate operations on superconducting quantum processors; through precise regulation of the electromagnetic control signals of qubits, the required quantum logic operations can be reliably realized.

From the perspective of technical application prospects, this protocol has broad application potential in the field of quantum communication. The use of quantum Fourier transform makes the construction of measurement bases more systematic and standardized, and this characteristic is advantageous for unified implementation on different quantum hardware platforms. In quantum network architectures, this protocol can be used to build core transmission modules for distributed quantum computing, realizing the transmission of quantum information between different computing nodes. In addition, HOLO has also explored application schemes for this technology in specific scenarios such as quantum secure communication and distributed quantum measurement. With the continuous advancement of quantum hardware technology, particularly the continuous improvement in qubit performance and quantity, this transmission protocol is expected to play an important role in future quantum information systems, providing key technical support for building large-scale quantum networks.

About MicroCloud Hologram Inc.

MicroCloud Hologram Inc. (NASDAQ: HOLO) is committed to the research and development and application of holographic technology. Its holographic technology services include holographic light detection and ranging (LiDAR) solutions based on holographic technology, holographic LiDAR point cloud algorithm architecture design, technical holographic imaging solutions, holographic LiDAR sensor chip design, and holographic vehicle intelligent vision technology, providing services to customers offering holographic advanced driving assistance systems (ADAS). MicroCloud Hologram Inc. provides holographic technology services to global customers. MicroCloud Hologram Inc. also provides holographic digital twin technology services and owns proprietary holographic digital twin technology resource libraries. Its holographic digital twin technology resource library utilizes a combination of holographic digital twin software, digital content, space data-driven data science, holographic digital cloud algorithms, and holographic 3D capture technology to capture shapes and objects in 3D holographic form. MicroCloud Hologram Inc. focuses on developments such as quantum computing and quantum holography, with cash reserves exceeding 3 billion RMB, and plans to invest more than 400 million in USD from the cash reserves to engage in blockchain development, quantum computing technology development, quantum holography technology development, and derivatives and technology development in frontier technology fields such as artificial intelligence AR. MicroCloud Hologram Inc.’s goal is to become a global leading quantum holography and quantum computing technology company.

Safe Harbor Statement

This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company’s goals and strategies; the Company’s future business development; product and service demand and acceptance; changes in technology; economic conditions; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic; financial condition and results of operations; the expected growth of the holographic industry and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission (“SEC”), including the Company’s most recently filed Annual Report on Form 10-K and current report on Form 6-K and its subsequent filings. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.